Abstract
Experimental stem cell therapy (ESCT) as a mode of therapeutic treatment is widely available in India in spite of regulatory prohibition of such practice and little scientific evidence in support of its medical efficacy. In our view, it is especially the varied institutional set-ups and modes of functioning of therapeutic service-providing centres that make ESCT a lucrative enterprise. But very little is known about how such providers circumvent scientific and regulatory frameworks and are able to successfully sustain and expand this enterprise. In this article we argue that such providers thrive through ‘bionetworking’− informal forms of socio-scientific and entrepreneurial liaison − in the context of their institutional embeddings. In contrast with moral and generalising explanations for the spread of stem cell therapies in India in terms of neoliberal pressures, we illustrate how variable institutional embeddings motivate therapy providers to actively create and mobilise dialects of a dominant bioethics discourse. We categorised the therapy providers into three groups: public, private and independent practitioners. The differences show that institutional embeddings are crucial to the understanding of the diverse motivations, therapeutic practices and patient recruitment strategies that we analyse on the basis of various economic values, entrepreneurial logics and bioethical discursive dialects.
Similar content being viewed by others
References
Bharadwaj, A. and Glasner, P. (2009) Local Cells, Global Science: The Rise of Embryonic Stem Cell Research in India. London and New York: Routledge.
Cohen, C.B. and Cohen, P.J. (2010) International stem cell tourism and the need for effective regulation. Part I: Stem cell tourism in Russia and India: Clinical research, innovative treatment, or unproven hype? Kennedy Institute of Ethics Journal 20 (1): 27–49.
DBT-ICMR (Department of Biotechnology and Indian Council of Medical Research). (2007) Guidelines for Stem Cell Research and Therapy. New Delhi, India: Director General, Indian Council of Medical Research, From http://www.icmr.nic.in/stem_cell/stem_cell_guidelines.pdf, accessed November 2012.
Dey, S. (2007) Selling stem cells. ExpressPharma. From http://www.expresspharmaonline.com/20071215/market01.shtml, accessed March 2011.
Enserink, M. (2006) Biomedicine: Selling the stem cell dream. Science 313 (5784): 160–163.
ExpressPharma. (2006) Stem cell research: The Indian perspective, http://www.expresspharmaonline.com/cgibin/ecprint/MasterPFP.cgi?doc=, accessed 21 February 2008.
Foucault, M. (1978) The History of Sexuality VI: An Introduction. New York: Vintage Books.
Hyun, I. (2010) Allowing innovative stem cell-based therapies outside of clinical trials: Ethical and policy challenges. The Journal of Law, Medicine and Ethics 38 (2): 277–285.
Jayaraman, K. (2005 Indian regulations fail to monitor growing stem-cell use in clinics. Nature 434 (17): 259.
Jones, B. (2008) New guidelines drawn up in fight against rogue stem cell clinics. BioNews, 8 December 2008, http://www.bionews.org.uk/page_13604.asp, accessed 12 October 2009.
Patra, P.K. and Sleeboom-Faulkner, M. (2009) Bionetworking: Experimental stem cell therapy and patient recruitment in India. Anthropology and Medicine 16 (2): 147–163.
Qiu, J. (2009) Trading on hope. Nature Biotechnology 7 (9): 790–792.
Sharma, A. (2006) Stem cell research in India. CellNews, http://www.geocities.com/giantfideli/art/CellNEWS_Stem_Cells_India_Upd.html, accessed 14 March 2010.
Sleeboom-Faulkner, M. (2010) Contested embryonic culture in Japan: Public discussion, and human embryonic stem cell research in an aging welfare society. Medical Anthropology 29 (1): 44–70.
Srinivasan, S. (2006) Clinical trials, Part IV: Rogue research in the guise of stem cell therapy. InfochangeHealth, http://infochangeindia.org/index.php?option=com_content&task=view&id=278&Itemid=44, accessed 19 November 2012.
Taylor, P.L. (2010) Overseeing innovative therapy without mistaking it for research: A function-based model based on old truths, new capacities, and lessons from stem cells. Journal of Law, Medicine and Ethics 38 (2): 286–301.
The Hindu Business Line. (2009) Stempeutics eyes stem cell drug in 2011. The Hindu Business Line, http://www.thehindubusinessline.com/2009/03/25/stories/2009032551430500.htm, last accessed 19 November 2012.
The Hindustan Times. (2006) Stem Cell Trials to Start at AIIMS, 13 November 2006. Stem Cell Research Blog, ‘Stem Cell Research in Heart Disease and other Ailments at all India Institute of Medical Sciences’, http://stemcell.taragana.net/archive/stem-cell-research-in-heart-disease-and-other-ailments-at-all-india-institute-of-medical-sciences/, accessed 10 July 2010.
The Indian Express. (2009) AIIMS drops two stem-cell trials due to poor patient response. 7 February 2009, http://www.indianexpress.com/news/aiims-drops-two-stemcell-trials-due-to-poor/420224/, accessed 12 January 2010.
Acknowledgements
The research for this article has been conducted under ESRC grants RES-062-23-0215. We thank the anonymous reviewers of BioSocieties for their very useful comments.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Patra, P., Sleeboom-Faulkner, M. Discursive dialects of bioethics: Understanding the institutional embeddings of human stem cell experimentation in India. BioSocieties 8, 75–92 (2013). https://doi.org/10.1057/biosoc.2012.33
Published:
Issue Date:
DOI: https://doi.org/10.1057/biosoc.2012.33